【TLC Biosciences Corp.】Q1 2026 EPS -0.10 NTD
TLC Biosciences Corp. reported its Q1 2026 financial results with an EPS of -0.10 NTD, operating revenue of 0.45 billion NTD, and net income after tax of -0.15 billion NTD. The company is navigating the financial challenges typical of the biotechnology and medical industry's R&D phase.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 12, 2026 at 08:00 (1727h 0m after Published)
- 🤖 AI Analyzed: May 12, 2026 at 08:20 (20 min after Collected)
Company code: 6838
Company name: TLC Biosciences Corp.
Industry: Biotechnology and medical industry
Year/Quarter: Q1 2026
Basic Earnings Per Share (EPS): -0.10 NTD
Operating revenue: 0.45 billion NTD
Net income after tax: -0.15 billion NTD
Company name: TLC Biosciences Corp.
Industry: Biotechnology and medical industry
Year/Quarter: Q1 2026
Basic Earnings Per Share (EPS): -0.10 NTD
Operating revenue: 0.45 billion NTD
Net income after tax: -0.15 billion NTD